June 9, 2016 / 7:57 PM / 2 years ago

Valeant said to weigh sale of Egyptian drugmaker Amoun: Bloomberg

(Reuters) - Valeant Pharmaceuticals International Inc VRX.N (VRX.TO) is considering the sale of Egyptian drugmaker Amoun Pharmaceutical Co to accelerate its debt-reduction plan, Bloomberg reported, citing people with knowledge of the matter.

Valeant is working with Goldman Sachs Group on the sale, which is at a preliminary stage, according to the report. It is also weighing a sale of some of its Latin American operations, Bloomberg reported.

    Valeant bought Amoun for about $800 million last year.

    Valeant, which earlier in the week reported lower-than-expected first quarter profit, could not be immediately be reached for comment.

    The Canadian company has said that it is aiming to lower its almost $30 billion debt.

    Reporting by Ankur Banerjee in Bengaluru; Editing by Shounak Dasgupta

    0 : 0
    • narrow-browser-and-phone
    • medium-browser-and-portrait-tablet
    • landscape-tablet
    • medium-wide-browser
    • wide-browser-and-larger
    • medium-browser-and-landscape-tablet
    • medium-wide-browser-and-larger
    • above-phone
    • portrait-tablet-and-above
    • above-portrait-tablet
    • landscape-tablet-and-above
    • landscape-tablet-and-medium-wide-browser
    • portrait-tablet-and-below
    • landscape-tablet-and-below